A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4–6 years

Marshall, H., Nolan, T., Roberton, D., Richmond, P., Lambert, S. W., Jacquet, J. M. and Schuerman, L. (2006) A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4–6 years. Vaccine, 24 35-36: 6120-6128. doi:10.1016/j.vaccine.2006.05.017


Author Marshall, H.
Nolan, T.
Roberton, D.
Richmond, P.
Lambert, S. W.
Jacquet, J. M.
Schuerman, L.
Title A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4–6 years
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-110X
1873-2518
Publication date 2006-08-28
Year available 2006
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2006.05.017
Volume 24
Issue 35-36
Start page 6120
End page 6128
Total pages 9
Place of publication Oxford, United Kingdom
Publisher Elsevier
Language eng
Subject 111403 Paediatrics
111716 Preventive Medicine
Abstract This study evaluated GSK's combined DTPa-IPV vaccine (Infanrix™-IPV) given as a fifth consecutive acellular pertussis booster dose in conjunction with the second dose of MMR vaccine (Priorix™) in children aged 4–6 years. The immunogenicity and reactogenicity of this vaccine regimen was compared with separate injections of DTPa and IPV when given concomitantly with MMR. A cohort of 362 children previously primed with four doses of DTPa and OPV, and a single dose of MMR were randomized to receive either DTPa-IPV + MMR (N = 181) or DTPa + IPV + MMR (N = 181). Antibody concentrations were measured prior to and 1 month after the booster dose. After immunisation all subjects from both groups had seroprotective antibody levels against diphtheria, tetanus and the three poliovirus serotypes, ≥96% showed vaccine response to PT, FHA and PRN, all were seropositive to mumps and rubella, and all but one subject were seropositive to measles. Immunogenicity results for each component antigen were similar for DTPa-IPV and separately co-administered DTPa and IPV. Local reactions were common with 24.0% and 31.1% of children experiencing swelling >50 mm at the DTPa-IPV and DTPa injection sites, respectively. The DTPa-IPV combination did not increase the incidence or intensity of adverse events compared with separately administered DTPa + IPV. The response to the concomitantly administered MMR vaccine was similar in the two groups and similar to previously reported responses for a second dose of MMR. This combined DTPa-IPV vaccine has a similar reactogenicity profile to DTPa, is immunogenic when given as a booster dose at 4–6 years of age, and has no impact on the immunogenicity of a co-administered second dose of MMR vaccine.
Keyword DTPa-IPV
Booster
Measles-mumps-rubella
Local swelling reactions
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Available online 2 June 2006.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
Institute for Molecular Bioscience - Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 224 Abstract Views  -  Detailed Statistics
Created: Thu, 08 Jan 2009, 15:58:53 EST by Judy Dingwall on behalf of Clinical Medical Virology Centre